Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00648388 | Fasting Study of Cilostazol Tablets 100 mg and Pletal® Tablets 100 mg | PHASE1 | COMPLETED | 44 | — | — | Mar 1, 2004 | May 1, 2004 | Apr 23, 2024 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Cilostazol Tablets 100 mg |
| 2 | ACTIVE_COMPARATOR | Pletal® Tablets 100 mg |
| Name | Type | Description |
|---|---|---|
| Cilostazol Tablets 100 mg | DRUG | 100mg, single dose fasting |
| Pletal® Tablets 100 mg | DRUG | 100 single dose fasting |
Inclusion Criteria: 1. Age: 18 years and older. 2. Sex: Male and/or non-pregnant, non-lactating female. 1. Women of childbearing potential must have negative serum beta human chorionic gonadotropin (beta-HCG) pregnancy tests performed within 14 days prior to the start of the study and on the ev...